IA17 Druggable Vulnerabilities in Therapy-Resistant Lung Cancers
Publication
, Conference
Wood, KC
Published in: Journal of Thoracic Oncology
February 2020
Duke Scholars
Published In
Journal of Thoracic Oncology
DOI
ISSN
1556-0864
Publication Date
February 2020
Volume
15
Issue
2
Start / End Page
S6 / S6
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Wood, K. C. (2020). IA17 Druggable Vulnerabilities in Therapy-Resistant Lung Cancers. In Journal of Thoracic Oncology (Vol. 15, pp. S6–S6). Elsevier BV. https://doi.org/10.1016/j.jtho.2019.12.017
Wood, K. C. “IA17 Druggable Vulnerabilities in Therapy-Resistant Lung Cancers.” In Journal of Thoracic Oncology, 15:S6–S6. Elsevier BV, 2020. https://doi.org/10.1016/j.jtho.2019.12.017.
Wood KC. IA17 Druggable Vulnerabilities in Therapy-Resistant Lung Cancers. In: Journal of Thoracic Oncology. Elsevier BV; 2020. p. S6–S6.
Wood, K. C. “IA17 Druggable Vulnerabilities in Therapy-Resistant Lung Cancers.” Journal of Thoracic Oncology, vol. 15, no. 2, Elsevier BV, 2020, pp. S6–S6. Crossref, doi:10.1016/j.jtho.2019.12.017.
Wood KC. IA17 Druggable Vulnerabilities in Therapy-Resistant Lung Cancers. Journal of Thoracic Oncology. Elsevier BV; 2020. p. S6–S6.
Published In
Journal of Thoracic Oncology
DOI
ISSN
1556-0864
Publication Date
February 2020
Volume
15
Issue
2
Start / End Page
S6 / S6
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology